Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Authors
Keywords
-
Journal
International Journal of Clinical Oncology
Volume 25, Issue 5, Pages 801-809
Publisher
Springer Science and Business Media LLC
Online
2020-04-03
DOI
10.1007/s10147-020-01666-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Carbon ion irradiation enhances the antitumor efficacy of dual immune checkpoint blockade therapy both for local and distant sites in murine osteosarcoma
- (2019) Yutaka Takahashi et al. Oncotarget
- Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy
- (2019) Maxim Shevtsov et al. Frontiers in Oncology
- Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
- (2019) Ou Yamaguchi et al. Thoracic Cancer
- Base excision repair regulates PD-L1 expression in cancer cells
- (2019) Tiara Bunga Mayang Permata et al. ONCOGENE
- Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy
- (2019) Tsung-Wei Chen et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Comparison of the effects of photon, proton and carbon-ion radiation on the ecto-calreticulin exposure in various tumor cell lines
- (2019) Yangle Huang et al. Annals of Translational Medicine
- Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer
- (2018) Atsushi Ogura et al. EUROPEAN JOURNAL OF CANCER
- Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors
- (2018) Jason J. Luke et al. JOURNAL OF CLINICAL ONCOLOGY
- High linear energy transfer carbon-ion irradiation increases the release of the immune mediator high mobility group box 1 from human cancer cells
- (2018) Masahiro Onishi et al. JOURNAL OF RADIATION RESEARCH
- Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma
- (2018) Kirtesh R. Patel et al. OncoImmunology
- Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
- (2018) Jun Gong et al. Journal for ImmunoTherapy of Cancer
- ATR kinase inhibitor AZD6738 potentiates CD8+ T cell–dependent antitumor activity following radiation
- (2018) Frank P. Vendetti et al. JOURNAL OF CLINICAL INVESTIGATION
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers
- (2018) Shu-Fen Chiang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immune mechanisms mediating abscopal effects in radioimmunotherapy
- (2018) María E. Rodriguez-Ruiz et al. PHARMACOLOGY & THERAPEUTICS
- Complete tumor response of a locally advanced lung large-cell neuroendocrine carcinoma after palliative thoracic radiotherapy and immunotherapy with nivolumab
- (2018) Charlotte Mauclet et al. LUNG CANCER
- Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer
- (2017) Xiaomei Gong et al. Journal of Thoracic Oncology
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
- (2017) Narek Shaverdian et al. LANCET ONCOLOGY
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of the HDAC/Suv39/G9a pathway restores the expression of DNA damage-dependent major histocompatibility complex class I-related chain A and B in cancer cells
- (2017) Nakako Izumi Nakajima et al. ONCOLOGY REPORTS
- cGAS is essential for the antitumor effect of immune checkpoint blockade
- (2017) Hua Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
- (2017) Hiro Sato et al. Nature Communications
- DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
- (2017) Claire Vanpouille-Box et al. Nature Communications
- Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients
- (2017) Daichi Fujimoto et al. Scientific Reports
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment
- (2017) Erik S. Anderson et al. Journal for ImmunoTherapy of Cancer
- Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming
- (2016) M. E. Rodriguez-Ruiz et al. CANCER RESEARCH
- PD‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
- (2016) Abul Azad et al. EMBO Molecular Medicine
- PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis
- (2016) Markus Hecht et al. EUROPEAN JOURNAL OF CANCER
- Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer
- (2016) S.H. Lim et al. EUROPEAN JOURNAL OF CANCER
- Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial
- (2016) Antonin Levy et al. EUROPEAN JOURNAL OF CANCER
- Programmed death-ligand 1 expression in rectal cancer
- (2016) G. Jomrich et al. European Surgery-Acta Chirurgica Austriaca
- The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
- (2016) Nan Zhang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors
- (2016) Jéssica Ribeiro Gomes et al. JOURNAL OF IMMUNOTHERAPY
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression
- (2016) Miao-Fen Chen et al. Oncotarget
- Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma
- (2016) E. Liniker et al. OncoImmunology
- Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies
- (2016) B. Seliger HLA
- PD-1/PD-L1 inhibitors
- (2015) Joel Sunshine et al. CURRENT OPINION IN PHARMACOLOGY
- Technology for Innovation in Radiation Oncology
- (2015) Indrin J. Chetty et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Carbon-ion beams induce production of an immune mediator protein, high mobility group box 1, at levels comparable with X-ray irradiation
- (2015) Y. Yoshimoto et al. JOURNAL OF RADIATION RESEARCH
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adaptive Immune Resistance: How Cancer Protects from Immune Attack
- (2015) A. Ribas Cancer Discovery
- PD-1 Restrains Radiotherapy-Induced Abscopal Effect
- (2015) S. S. Park et al. Cancer Immunology Research
- Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing
- (2015) Sofia R. Gameiro et al. Oncotarget
- Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
- (2014) S. J. Dovedi et al. CANCER RESEARCH
- STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
- (2014) Liufu Deng et al. IMMUNITY
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- HLA Class I Expression and Its Alteration by Preoperative Hyperthermo-Chemoradiotherapy in Patients with Rectal Cancer
- (2014) Hiro Sato et al. PLoS One
- Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
- (2014) A. B. Sharabi et al. Cancer Immunology Research
- Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death
- (2014) Encouse B Golden et al. OncoImmunology
- IFN-γ Mediates the Antitumor Effects of Radiation Therapy in a Murine Colon Tumor
- (2013) Scott A. Gerber et al. AMERICAN JOURNAL OF PATHOLOGY
- Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists
- (2013) T Yamazaki et al. CELL DEATH AND DIFFERENTIATION
- Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
- (2013) Jing Zeng et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING
- (2013) Andrea Ablasser et al. NATURE
- Immunogenic Tumor Cell Death Induced by Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma
- (2012) Yoshiyuki Suzuki et al. CANCER RESEARCH
- Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA
- (2012) J. Wu et al. SCIENCE
- Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
- (2012) L. Sun et al. SCIENCE
- The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon-Dependent Innate and Adaptive Immunity
- (2011) B. C. Burnette et al. CANCER RESEARCH
- Maximizing Tumor Immunity With Fractionated Radiation
- (2011) Dörthe Schaue et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
- (2010) Taro Kawai et al. NATURE IMMUNOLOGY
- Chemotherapy and radiotherapy: Cryptic anticancer vaccines
- (2010) Yuting Ma et al. SEMINARS IN IMMUNOLOGY
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
- (2009) M. Z. Dewan et al. CLINICAL CANCER RESEARCH
- Influence of Hsp70 and HLA-E on the killing of leukemic blasts by cytokine/Hsp70 peptide-activated human natural killer (NK) cells
- (2008) Stefan Stangl et al. CELL STRESS & CHAPERONES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started